EFFICACY AND SAFETY OF PENTAVALENT HUMAN-BOVINE REASSORTANT ROTAVIRUS VACCINE WHEN ADMINISTERED WITH GREATER THAN 10 WEEKS BETWEEN DOSES

被引:12
作者
Goveia, Michelle G. [1 ]
Suprun, Leora [1 ]
Itzler, Robbin F. [1 ]
McFetridge, Richard [1 ]
Dallas, Michael J. [1 ]
Kuter, Barbara J. [1 ]
机构
[1] Merck & Co Inc, West Point, PA 19486 USA
关键词
rotavirus; RotaTeq; pentavalent rotavirus vaccine; dosing window;
D O I
10.1097/INF.0b013e3181be6257
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The pentavalent human-bovine reassortant rotavirus vaccine is indicated as a 3-dose series with first dose administered orally at 6 to 12 weeks with subsequent doses at 4 to 10 week intervals. In pre-licensure phase III trials, the majority followed this schedule, but there were 2956 instances where infants received a dose of pentavalent human-bovine reassortant rotavirus vaccine/placebo >10 weeks after the previous dose. Among this subset, the efficacy against any severity of disease, the reduction in utilization of healthcare resources and the safety profile after vaccination were comparable with overall results.
引用
收藏
页码:263 / 265
页数:3
相关论文
共 14 条
[1]  
*AM AC PED COMM IN, 2009, PEDIATRICS, P1412
[2]  
[Anonymous], PROD APPR INF LIC AC
[3]   Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life [J].
Block, Stan L. ;
Vesikari, Timo ;
Goveia, Michelle G. ;
Rivers, Stephen B. ;
Adeyi, Ben A. ;
Dallas, Michael J. ;
Bauder, Jeffrey ;
Boslego, John W. ;
Heaton, Penny M. .
PEDIATRICS, 2007, 119 (01) :11-18
[4]   The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine [J].
Dennehy, Penelope H. ;
Goveia, Michelle G. ;
Dallas, Michael J. ;
Heaton, Penny M. .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2007, 11 :S36-S42
[5]  
Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P1
[6]   THE EFFECTS OF INFANT-FEEDING ON ROTAVIRUS-INDUCED GASTROENTERITIS - A PROSPECTIVE-STUDY [J].
DUFFY, LC ;
BYERS, TE ;
RIEPENHOFFTALTY, M ;
LASCOLEA, LJ ;
ZIELEZNY, M ;
OGRA, PL .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1986, 76 (03) :259-263
[7]  
*EUR MED AG, SUMM PROD CHAR ROTAT
[8]   Rotavirus vaccines: current prospects and future challenges [J].
Glass, Roger I. ;
Parashar, Umesh D. ;
Bresee, Joseph S. ;
Turcios, Reina ;
Fischer, Theo K. ;
Widdowson, Marc-Alain ;
Jiang, Baoming ;
Gentsch, Jon R. .
LANCET, 2006, 368 (9532) :323-332
[9]  
HABER P, 2008, 48 ANN INT C ANT AG
[10]  
IRVING SA, 2008, 48 ANN INT C ANT AG